Drug Trial Radar · NCT03575793
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Jan 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
39
Actual
Start
Sep 6, 2018
Primary completion
Sep 25, 2023
Study completion Jul 1, 2024
Sponsor
- Lead sponsor
- Salma SabbourAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- BeyondSpring Pharmaceuticals Inc.; Bristol-Myers Squibb; Rutgers Cancer Institute of New Jersey
- First posted
- Jul 3, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label Phase I/II study, with a dose escalation part (Phase I) and a single-arm part (Phase II), in patients with recurrent SCLC who progressed after first-line platinum-based chemotherapy and who are candidates for second line therapy. No PK evaluation is planned in this study as nivolumab and ipilimumab are unlikely to alter plinabulin's PK, since the route of excretion is different.
Conditions
- Lung Cancer
- SCLC
Interventions
NivolumabDrug
A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1,) with immune checkpoint inhibitory and antineoplastic activities.
PlinabulinDrug
Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity originally developed by Nereus Pharmaceuticals, Inc., and now by BeyondSpring Pharmaceuticals, Inc. It belongs to the diketopiperazine class of compounds with a chemical name 2, 5-piperazinedione, 3-\[\[5-(1,1-dimethylethyl)-1H-imidazol-4-yl\[methylene\]-6-(phenylmethylene)-, (3Z,6Z) (trivial name t-butyl-dehydrophenylahistin).
IpilimumabDrug
Ipilimumab is a monoclonal antibody that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase I: Maximum Tolerated Dose (MTD)Time frame: Up to 42 days of first Plinabulin dose
- Progression-Free Survival (PFS)Time frame: Up to maximum of 9 months
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
City of Hope
Duarte, California
Moffitt Cancer Center
Tampa, Florida
University of Illinois Cancer Center
Chicago, Illinois
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana
Henry Ford Health System
Detroit, Michigan
University of Minnesota
Minneapolis, Minnesota
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey
Erlanger Health System
Chattanooga, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.